This page shows the latest NovoSeven news and features for those working in and with pharma, biotech and healthcare.
The haemophilia A with inhibitors category is currently dominated by Shire and Novo Nordisk with its Feiba and NovoSeven bypassing agents (PBAs).
The market for haemophilia A with inhibitors is currently dominated by Shire and Novo Nordisk with their Feiba and NovoSeven bypassing agents (PBAs).
The market for haemophilia A with inhibitors is currently dominated by Shire and Novo Nordisk with their Feiba and NovoSeven bypassing agents (PBAs).
for breakthrough bleeds which includes Shire's Feiba and Novo Nordisk's NovoSeven. ... Analysts have previously suggested that emicizumab could attack around half the revenues of NovoSeven, which made sales of almost $1.4bn in 2016, and eat into the
The drug will be used in conjunction with Novo's MixPro, the pre-filled device that was launched earlier this year and is already in use with the company's NovoSeven ... Novo's existing haemophilia A and B treatment for patients with inhibitors, NovoSeven
Normally associated with diabetes medicines, Novo has built a burgeoning business in the area of bleeding disorders, led by NovoSeven, which made $1.4bn in revenues in 2012.
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....